Cytarabine 2gm
| Product Overview | |
| Generic Name | Cytarabine 2gm |
| Brand Name(s) | Cytosar-U |
| Form | Vial, Injectable solution for IV |
| Strength | 2 g./ 20mL |
| Therapeutic Class | Antimetabolite antineoplastic (pyrimidine analog) |
| ATC Code | L01BC01 |
| Manufacturing & Regulatory | |
| Manufacturer | Pfizer |
| Country | India/USA/EU |
| GMP Compliance | WHO-GMP certified |
| DMF/CEP | Type II/III |
| COFEPRIS | Pending |
| Free Sale Certificate | Yes, available as COPP/CPP |
| Logistics & Export | |
| MOQ | 100 units |
| Shelf Life | 18 - 24 months |
| Storage | 2–8 °C |
| Incoterms | Ex-Works 30049049 |
| Lead Time | 7 to 10 Days |
| Documentation | |
| Certificate of Analysis (COA) | Yes—lot-specific Certificate of Analysis |
| CTD Summary | CTD proprietary; available under commercial agreement/license |
Description
Cytarabine is an antineoplastic antimetabolite, specifically a pyrimidine nucleoside analogue, used in chemotherapy protocols. Indicated in treatment for acute lymphocytic leukemia, acute granulocytic leukemia, erythroleukemia, and meningeal leukemia, administered by intravenous or intrathecal
